摘要
目的研究肥胖2型糖尿病患者血管内皮功能的影响因素及吡格列酮的治疗作用。方法新诊断肥胖2型糖尿病患者30例,正常对照组25例,治疗前后分别检测血清APN、HOMA-IR、TG、HDL、BMI,同时利用超声检测反应性充血肱动脉内径增加程度FMD。结果肥胖2型糖尿病患者FMD及APN水平较正常对照明显降低,吡格列酮治疗后FMD显著改善(7.15±3.20 vs10.36±4.55,P<0.01)、APN升高(6.94±2.58 mg/L vs 9.77±3.16 mg/L,P<0.01)。多元相关分析显示,FMD与APN、HDL呈显著正相关(r=0.592,r=0.306,P<0.01),与FBG、HOMA-IR呈负相关(r=-0.285,r=-0.291,P<0.01),与年龄、性别、BMI、TG无关。结论2型糖尿病患者存在明显的内皮功能紊乱及低脂联素血症,吡格列酮可通过多种途径起到改善血管内皮功能的作用。
Objective To investigate the effect of pioglitazone on endothelial dysfunction and serum adiponectin in newly detected type 2 diabetic patients with obesity.Methods The study included 30 type 2 diabetic patients with obesity and 25 healty subjects.The patients received pioglitazone at 15-30 mg daily for 16 weeks.The endothelium-dependent flow-mediated dilatatio（FMD）of brachial artery was determined with ultrasound,and the levels of APN,FBG,HDL,TG,HOMA-IR in all subjects were measured respectively at baseline and after treatment.Results Pioglitazone markedly improved FMD（7.15±3.20 vs 10.36±4.55,P〈0.01）and APN 6.94±2.58 mg/L vs 9.77 ±3.16 mg/L,P 〈0.01）,glycemic control and insulin sensitivity were improved.There was positive correlation between FMD and APN.Conclusion There are endothelial dysfunction and hypoadiponectin in type 2 diabetic patients with obesity,pioglitazone may improve endothelial function.
出处
《医学研究与教育》
CAS
2009年第1期23-25,共3页
Medical Research and Education
关键词
吡格列酮
2型糖尿病
内皮功能
脂联素
pioglitazone
type 2 diabetes
endothelial function
adiponectin
